SCHEMBL4201369

SCHEMBL4201369

O=c1c2sccc2nc(-c2ccc(F)cc2)n1NCc1ccc(Br)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43
RXFP1 Q9HBX9 5/20 0.43
TP53 P04637 1/20 0.41
MAPT P10636 4/20 0.40
USP2 O75604 1/20 0.40
NPSR1 Q6W5P4 4/20 0.38
ALDH1A1 P00352 3/20 0.37
GAA P10253 2/20 0.37
KDM4E B2RXH2 1/20 0.37
PDE7A Q13946 3/20 0.37
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4201045 0.89 RXFP1 (0.52) SMN1; SMN2MEN1LMNAKMT2ARXFP1
SCHEMBL4202606 0.85 NR1I3 (0.43) SMN1; SMN2MEN1LMNAKMT2ARXFP1
SCHEMBL4196795 0.83 SMN1; SMN2 (0.46) SMN1; SMN2MEN1LMNAKMT2AMAPT
SCHEMBL4236185 0.81 SMN1; SMN2 (0.67) SMN1; SMN2MEN1LMNAKMT2AMAPT
SCHEMBL4735977 0.79 SMN1; SMN2 (0.48) SMN1; SMN2MEN1LMNAKMT2ATP53
SCHEMBL4201370 0.78 SMN1; SMN2 (0.50) SMN1; SMN2MEN1LMNAKMT2AMAPT
SCHEMBL4233963 0.78 SMN1; SMN2 (0.48) SMN1; SMN2MEN1LMNAKMT2ATP53
SCHEMBL4195763 0.78 SMN1; SMN2 (0.48) SMN1; SMN2MEN1LMNAKMT2AMAPT
SCHEMBL4242353 0.78 SMN1; SMN2 (0.50) SMN1; SMN2MEN1LMNAKMT2AMAPT
SCHEMBL4239901 0.77 SMN1; SMN2 (0.54) SMN1; SMN2MEN1LMNAKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 SMN1; SMN2 3183/4885MEN1 4670/4885LMNA 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.